CVS Health Corporation

CVS

Healthcare Healthcare Plans

CVS Health Corporation’s revenue for fiscal 2025 (year ended December 2025) was $402.1 billion, up 7.85% from fiscal 2024.

Revenue
+5.37%
EPS
n/m
Free cash flow
+3,886.7%
Total debt
−7.83%

Quarter to September 2026, against a year earlier

89.35 0.44 −0.49%
Market cap
$114.9B
P/E
10.3×
Fwd P/E FY26e
12.8×
Dividend yield
2.98%
F-score
7/9
ROIC
7.44%
Net debt / EBITDA
3.6×
Payout ratio
0.3×

CVS Health Corporation (CVS) news

The news and the share price important stories, numbered as below

Share price since 16 October −3.3%

Stories the last two months, newest first

  1. 2 Other ·

    CVS plans to separate its retail pharmacy business by 2028

    CVS plans to split into two publicly traded companies by the first half of 2028. CVS Health will retain Aetna, Caremark and other healthcare businesses, while CVS Pharmacy will include about 9,000 stores and related operations. Shareholders are expected to receive shares in both companies, subject to approvals and other conditions.

    Reported by 42: 24/7 Wall St. · Investing.com · Investing.com · finance.yahoo.com · CNN · Proactive Investors · Moby · TIKR · healthcaredive.com · 24/7 Wall St. · 24/7 Wall St. · MT Newswires · Moby · Bloomberg · The Motley Fool · Barchart · GuruFocus.com · MarketBeat · Simply Wall St. · GuruFocus.com · Zacks · TheStreet · LA Times · retail-insight-network.com · MarketBeat · Trefis · 24/7 Wall St. · The Motley Fool · credaily.com · wwd.com · firstformoney.com · StockStory · MarketBeat · Simply Wall St. · 24/7 Wall St. · Zacks · finance.yahoo.com · pharmaceutical-technology.com · Business Wire · TheStreet · Benzinga · Barchart

  2. Guidance ·

    CVS expects Health Services earnings to trough in 2027

    CVS Health expects its Health Services segment to hit an earnings low in 2027, with adjusted operating income of at least $7 billion amid 340B declines, a weaker selling season and client membership losses. The segment returned to growth in 2025 and is expected to grow again after 2027. Company-wide adjusted EPS is forecast at $8.65 or more in 2027.

    Reported by Trefis

  3. Commentary ·

    Zacks cites Aetna recovery and PBM pressures in CVS stock outlook

    CVS's recovery case is improving as Aetna's third-quarter 2026 adjusted operating income rose to $912 million and its medical benefit ratio improved to 91.3%. Stronger cash flow supported debt repayment and plans to resume buybacks. Persistent PBM, reimbursement and membership pressures weigh on the outlook, while management expects further Aetna margin improvement in 2027.

    Reported by Zacks

  4. Commentary ·

    Zacks assigns CVS a Rank #2 (Buy) in its trending-stock review

    CVS shares gained 1.7% over the past month, outperforming the S&P 500 but trailing its industry. Zacks assigns CVS a Rank #2 (Buy), citing earnings estimate revisions: current-year and next-year estimates rose 2.9% and 1.5% over the past month, though the current-quarter estimate fell 11.9%. CVS beat revenue and EPS expectations in each of the past four quarters.

    Reported by Zacks

  5. Analyst ·

    Zacks upgrades CVS to Rank #2 (Buy)

    CVS Health was upgraded to Zacks Rank #2 (Buy) after its consensus earnings estimate for fiscal 2026 rose 2.8% over the past three months to $8.17 per share, flat year over year. Zacks says the upgrade reflects improving earnings expectations that may support near-term share-price gains.

    Reported by Zacks

  6. Product ·

    CVS Caremark expands its use of lower-cost biosimilars

    CVS Caremark says its biosimilar strategy is expanding access to lower-cost treatments while preserving clinical standards. The company reports approximately $3.3 billion in gross savings for clients and members from its approach. It is accelerating biosimilar adoption, removing Humira from many client formularies and shifting Stelara coverage toward lower-cost biosimilars as they become available.

    Reported by 2: ACCESS Newswire · Simply Wall St.

  7. Legal ·

    CVS challenges Tennessee’s pharmacy benefit manager ownership ban

    CVS Health has sued in federal court to challenge Tennessee’s law barring pharmacies from owning pharmacy benefit managers. The dispute targets CVS’s integrated pharmacy and PBM model and follows its plan to separate those operations into two companies. CVS says Tennessee patients’ pharmacy services will continue without interruption as the case proceeds. The outcome could affect how CVS operates in the state.

    Reported by Simply Wall St.

  8. Commentary ·

    Simply Wall St. says CVS shares trade below peer earnings multiples

    CVS Health shares have gained 38.7% over three years but recently pulled back, closing at $83.85 as the company plans to split into retail pharmacy and insurance/healthcare services businesses in 2028. The stock trades at 9.7 times earnings, below healthcare industry and peer averages of 24.9 and 20.3, respectively. The valuation outlook remains subject to the planned breakup and legal disputes over Medicare Advantage ratings.

    Reported by Simply Wall St.

  9. 1 Results ·

    CVS reports $108.4 billion in revenue and raises its 2026 outlook

    CVS Health reported third-quarter revenue of $108.4 billion, up 5.4% year over year, and adjusted earnings of $2.09 per share, beating estimates. The company raised its 2026 adjusted EPS guidance to at least $8.20 and operating cash flow guidance to at least $15.5 billion. Health Care Benefits operating income improved, while pharmacy reimbursement pressure and elevated medical costs remained concerns.

    Reported by 5: StockStory · Zacks · GuruFocus.com · Zacks · Zacks

  10. Other ·

    Yahoo Finance Video reports CVS has dropped retail spin-off plans

    CVS reversed course on its $70 billion Aetna merger strategy, abandoning plans to spin off its retail business as it reassesses its business model and the future of its pharmacy and insurance operations.

    Reported by finance.yahoo.com

More headlines